In this context we hypothesized that genetic changes in the MGMT, IDH1/2 and BRAF genes, which are currently considered to be most relevant for molecular diagnostics in glial tumors[11], could represent a new diagnostic tool for the integration of “boarder-line cases” based on their specific genetic fingerprints. This evidence concerns the gene IDH1 and glioma.